219 related articles for article (PubMed ID: 21632861)
41. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
42. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
43. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
[TBL] [Abstract][Full Text] [Related]
44. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas.
Matsunaga T; Takahashi H; Ohnuma N; Tanabe M; Yoshida H; Iwai J; Shirasawa H; Simizu B
Cancer Res; 1991 Jun; 51(12):3148-52. PubMed ID: 2039993
[TBL] [Abstract][Full Text] [Related]
45. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
46. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Wang Q; Diskin S; Rappaport E; Attiyeh E; Mosse Y; Shue D; Seiser E; Jagannathan J; Shusterman S; Bansal M; Khazi D; Winter C; Okawa E; Grant G; Cnaan A; Zhao H; Cheung NK; Gerald W; London W; Matthay KK; Brodeur GM; Maris JM
Cancer Res; 2006 Jun; 66(12):6050-62. PubMed ID: 16778177
[TBL] [Abstract][Full Text] [Related]
47. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma.
Takagi D; Tatsumi Y; Yokochi T; Takatori A; Ohira M; Kamijo T; Kondo S; Fujii Y; Nakagawara A
Cancer Sci; 2013 May; 104(5):563-72. PubMed ID: 23360421
[TBL] [Abstract][Full Text] [Related]
48. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
49. Control of ALK (wild type and mutated forms) phosphorylation: specific role of the phosphatase PTP1B.
Boutterin MC; Mazot P; Faure C; Doly S; Gervasi N; Tremblay ML; Vigny M
Cell Signal; 2013 Jun; 25(6):1505-13. PubMed ID: 23499906
[TBL] [Abstract][Full Text] [Related]
50. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
51. Expression of TrkC in favorable human neuroblastomas.
Yamashiro DJ; Nakagawara A; Ikegaki N; Liu XG; Brodeur GM
Oncogene; 1996 Jan; 12(1):37-41. PubMed ID: 8552397
[TBL] [Abstract][Full Text] [Related]
52. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
53. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.
Ren H; Tan ZP; Zhu X; Crosby K; Haack H; Ren JM; Beausoleil S; Moritz A; Innocenti G; Rush J; Zhang Y; Zhou XM; Gu TL; Yang YF; Comb MJ
Cancer Res; 2012 Jul; 72(13):3312-23. PubMed ID: 22570254
[TBL] [Abstract][Full Text] [Related]
54. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
[TBL] [Abstract][Full Text] [Related]
55. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
56. Differential Impact of
O'Donohue T; Gulati N; Mauguen A; Kushner BH; Shukla N; Rodriguez-Sanchez MI; Bouvier N; Roberts S; Basu E; Cheung NK; Modak S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250410
[TBL] [Abstract][Full Text] [Related]
57. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
[TBL] [Abstract][Full Text] [Related]
58. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.
Rassidakis GZ; Goy A; Medeiros LJ; Jiang Y; Thomaides A; Remache Y; Cabanillas F; Sarris AH; Gilles F
Clin Cancer Res; 2003 Jun; 9(6):2213-20. PubMed ID: 12796388
[TBL] [Abstract][Full Text] [Related]
60. Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C; Fassunke J; Ernst A; Schömig-Markiefka B; Merkelbach-Bruse S; Bartenhagen C; Cartolano M; Ackermann S; Theissen J; Blattner-Johnson M; Jones B; Schramm K; Altmüller J; Nürnberg P; Ortmann M; Berthold F; Peifer M; Büttner R; Westermann F; Schulte JH; Simon T; Hero B; Fischer M
Br J Cancer; 2023 Apr; 128(8):1559-1571. PubMed ID: 36807339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]